Barcitinib (Olumiant) is currently approved by FDA for Emergency Use Authorization in Covid 19. It is given orally.
Barcitinib is indicated for the treatment of COVID-19 in hospitalized adults and pediatric patients 2 yrs of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation.

Warnings and precautions
• Serious infections
• Avoid Barcitinib in patients with known active tuberculosis
• Avoid the use of live vaccines with baricitinib
• Thrombosis

Coronavirus Vaccines and Therapeutics